Valuation Assessment for Hims & Hers Health Inc HIMS
On August 26, 2026, Hims & Hers Health Inc (HIMS) shares fell 6.0% to $29.83, reflecting a challenging market environment for the company. The stock has experienced significant volatility over the past year, trading within a 52-week range of $13.74 to $65.30.
- GF Value™ verdict: Current price of $29.83 is 30.6% below the GF Value™ estimate of $42.98.
- GF Score™ of 81/100 indicates a strong overall rating.
- Most notable signal: Insider activity shows net selling of $58.4M over the past 12 months.
Is HIMS Overvalued or Undervalued?
The current price of Hims & Hers Health Inc at $29.83 is significantly below the GF Value™ estimate of $42.98, suggesting that the stock is undervalued by approximately 30.6%. However, it is essential to approach this valuation with caution due to the company’s status as a loss-making entity. GF Value™ is a proprietary estimate derived from historical trading multiples, business growth trends, and future performance forecasts. For a company like HIMS, which is currently unprofitable and cash-flow negative, relying solely on traditional earnings-based valuation metrics such as price-to-earnings (P/E) can be misleading. Therefore, the GF Value™ verdict should be interpreted as a directional warning rather than a precise fair-value target.
While the GF Value™ suggests an opportunity, the risk of a potential value trap cannot be ignored. The company's financial challenges and lack of profitability raise questions about its ability to sustain long-term growth and deliver on shareholder expectations. Investors should consider these factors when evaluating the stock's current valuation in relation to its future prospects.
How Does HIMS's Valuation Compare to Its History?
| Metric | Current | Historical |
|---|---|---|
| P/E Ratio (TTM) | N/A | 65.8x (5-Year Median) |
| Forward P/E | 2485.9x | N/A |
Given that traditional P/E analysis is not applicable due to HIMS's unprofitability, it can be noted that the stock is trading significantly above its historical valuation metrics, particularly when compared to its 5-year median P/E of 65.8x. The forward P/E of 2485.9x further underscores the challenges in applying earnings-based evaluations to this company. This discrepancy aligns with the cautious interpretation of the GF Value™, emphasizing that while the stock appears undervalued based on price alone, it is essential to consider the underlying financial realities.
What Does HIMS's GF Score™ Tell Us?
The GF Score™ is a composite rating that assesses a company's performance based on various fundamental factors, including financial strength, profitability, growth prospects, valuation, and momentum. Hims & Hers Health Inc has a GF Score™ of 81/100, indicating a strong overall rating. The company excels in growth (10/10) and valuation (8/10) while struggling in financial strength (4/10) and profitability (4/10).
| Metric | Rating |
|---|---|
| GF Score™ | 81/100 |
| Financial Strength | 4/10 |
| Profitability | 4/10 |
| Growth | 10/10 |
| Valuation | 8/10 |
| Momentum | 8/10 |
The strong growth rank indicates that HIMS is positioned for potential expansion, which may attract investor interest. However, the weaker financial strength and profitability ranks highlight significant risks that could impact the company’s ability to convert growth into sustainable profits. This mixed performance across different metrics suggests a cautious approach to HIMS's overall valuation and investment potential.
What Are Gurus and Insiders Doing with HIMS?
Currently, four gurus hold Hims & Hers Health Inc, with three increasing their positions while two have trimmed their holdings in recent quarters. This activity reflects a mixed sentiment among experienced investors, which can be a critical indicator of future performance.
Additionally, insider activity presents a concerning picture; over the past 12 months, insiders bought shares totaling $1.2M but sold off $59.6M, resulting in a net selling figure of $58.4M. This trend of net selling by insiders could signal a lack of confidence in the company's short-term prospects and may warrant caution for potential investors considering HIMS as part of their portfolio.
What This Means for Investors
Based on the analysis, Hims & Hers Health Inc appears to be undervalued according to the GF Value™, but the significant risks associated with its unprofitability and insider selling suggest a cautious stance. While the growth potential is evident, the lack of financial strength and profitability raises red flags that investors should carefully consider. For a detailed overview of HIMS's financials, visit the Hims & Hers Health Inc HIMS stock page.
Frequently Asked Questions
What is HIMS's GF Score™?
HIMS has a GF Score™ of 81/100, indicating a strong overall rating based on its performance across several fundamental factors.
Is HIMS overvalued or undervalued?
According to GF Value™, HIMS is currently undervalued, with its stock price being approximately 30.6% below its estimated fair value.
What is HIMS's P/E ratio?
HIMS currently has no applicable P/E ratio due to its unprofitability, while the 5-year median P/E stands at 65.8x, showcasing a significant disconnect in valuation metrics.
This stock alert was generated using automated technology and GuruFocus financial data to provide readers with timely and accurate market reporting. This content was reviewed by GuruFocus editorial team prior to publication. Please send any questions or comments about this story to [email protected].
